Equities analysts expect Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) to report ($0.67) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Trillium Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.78). Trillium Therapeutics posted earnings per share of ($0.84) during the same quarter last year, which would indicate a positive year-over-year growth rate of 20.2%. The business is expected to announce its next earnings results on Friday, November 9th.
According to Zacks, analysts expect that Trillium Therapeutics will report full year earnings of ($2.49) per share for the current fiscal year, with EPS estimates ranging from ($2.60) to ($2.34). For the next financial year, analysts forecast that the business will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.53) to ($1.79). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Trillium Therapeutics.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.05).
Trillium Therapeutics stock traded down $0.01 during mid-day trading on Tuesday, reaching $3.71. 40,931 shares of the company were exchanged, compared to its average volume of 188,441. Trillium Therapeutics has a twelve month low of $3.60 and a twelve month high of $13.30.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Platinum Investment Management Ltd. acquired a new stake in shares of Trillium Therapeutics during the first quarter worth approximately $1,255,000. Baker BROS. Advisors LP increased its position in Trillium Therapeutics by 25.0% during the 2nd quarter. Baker BROS. Advisors LP now owns 511,763 shares of the biotechnology company’s stock valued at $3,071,000 after purchasing an additional 102,440 shares during the period. Renaissance Technologies LLC increased its position in Trillium Therapeutics by 245.3% during the 2nd quarter. Renaissance Technologies LLC now owns 144,000 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 102,300 shares during the period. Stanley Laman Group Ltd. increased its position in Trillium Therapeutics by 26.7% during the 2nd quarter. Stanley Laman Group Ltd. now owns 137,091 shares of the biotechnology company’s stock valued at $823,000 after purchasing an additional 28,907 shares during the period. Finally, Wealth Alliance Advisory Group LLC purchased a new position in Trillium Therapeutics during the 3rd quarter valued at $126,000. 48.62% of the stock is currently owned by institutional investors and hedge funds.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Read More: Asset Allocation and Your Retirement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.